Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial. (11th October 2021)

• Record Type: Journal Article
• Authors: Chan, Wei Yee; Counsell, Nicholas; de Tute, Ruth; De‐Silva, Dunnya; Phillips, Elizabeth H.; Cavenagh, Jamie; Adedayo, Toyin; Braganca, Nivette; Roddie, Claire; Streetly, Matthew; Schey, Stephen; Koh, Mickey B.C.; Crowe, Josephine; Morris, Treen C.; Cook, Gordon; Clifton‐Hadley, Laura; Rabin, Neil; Owen, Roger G.; Popat, Rakesh; Yong, Kwee L.
• Other Names: D'Sa Shirley investigator.; Virchis Andres investigator.; Quinn Michael investigator.; Crawley Charles investigator.; Pratt Guy investigator.; Cook Mark investigator.
• Is Part Of: British journal of haematology. Volume 196:Number 4(2022)
• Page Start: e33
• Page End: e37
• Publication Date: 2021-10-11
• Subjects: multiple myeloma -- autologous stem cell transplantation -- high dose therapy -- myeloma therapy; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.17903
• Languages: English
• ISSNs: 0007-1048